Gerald Chan

Gerald Chan co-founded Morningside in 1986. As a privately-held investment group, Morningside is active in both private equity and venture capital investments in North America, Europe and Asia. The group began its China investments in 1992 and remains active in China's internet, media and life science sectors.

Dr. Chan is currently a board member of Hang Lung Group as well as several biotechnology companies including Metacure, Critical Biologics, and Vaccine Technologies Inc. He is a trustee of Fudan University in Shanghai and the Chinese University of Hong Kong. He received his BS and MS degrees in Engineering from UCLA, a master's degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training at the Dana Farber Cancer Institute.